Wearing‐off scales in Parkinson's disease: Critique and recommendations

Wearing‐off occurs in the majority of patients with Parkinson's disease after a few years of dopaminergic therapy. Because a variety of scales have been used to estimate wearing‐off, the Movement Disorder Society commissioned a task force to assess their clinimetric properties. A systematic review was conducted to identify wearing‐off scales that have either been validated or used in Parkinson's patients. A scale was designated “Recommended” if it had been used in clinical studies beyond the group that developed it, if it had been specifically used in Parkinson's disease reports, and if clinimetric studies had established that it is valid, reliable, and sensitive. “Suggested” scales met 2 of the above criteria, and those meeting 1 were “Listed.” We identified 3 diagnostic and 4 severity rating scales for wearing‐off quantification. Two questionnaires met the criteria to be Recommended for diagnostic screening (questionnaires for 19 and 9 items), and 1 was Suggested (questionnaire for 32 items). Only the patient diaries were Recommended to assess wearing‐off severity, with the caveat of relatively limited knowledge of validity. Among the other severity assessment tools, the Unified Parkinson Disease Rating Scale version 3 and the version revised from the Movement Disorders Society were classified as Suggested, whereas the Treatment Response Scale was Listed. © 2011 Movement Disorder Society

[1]  Mark Stacy,et al.  Identification of motor and nonmotor wearing‐off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment , 2005, Movement disorders : official journal of the Movement Disorder Society.

[2]  M. Stacy The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson’s disease , 2010, Journal of Neural Transmission.

[3]  K. Dujardin,et al.  Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations , 2008, Movement disorders : official journal of the Movement Disorder Society.

[4]  R. M. Stewart,et al.  The sensitivity and specificity of the 9-item Wearing-off Questionnaire. , 2008, Parkinsonism & related disorders.

[5]  L. Lopiano,et al.  Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome , 2007, Movement disorders : official journal of the Movement Disorder Society.

[6]  S. Fahn Unified Parkinson's Disease Rating Scale , 1987 .

[7]  R. Hauser,et al.  Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations , 2008, Movement disorders : official journal of the Movement Disorder Society.

[8]  E. Tolosa,et al.  Validation of the “QUICK” questionnaire—A tool for diagnosis of “wearing‐off” in patients with Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[9]  G. Stebbins,et al.  Efficacy of a patient‐training videotape on motor fluctuations for on‐off diaries in parkinson's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.

[10]  K. Dujardin,et al.  Anxiety rating scales in Parkinson's disease: Critique and recommendations , 2008, Movement disorders : official journal of the Movement Disorder Society.

[11]  W. Oertel,et al.  Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility—an open-label, 6-week study , 2010, Journal of Neural Transmission.

[12]  W Poewe,et al.  Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial , 2005, The Lancet.

[13]  D. Nyholm,et al.  Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations , 2009, Acta neurologica Scandinavica.

[14]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[15]  J. Obeso,et al.  When Do Levodopa Motor Fluctuations First Appear in Parkinson’s Disease? , 2010, European Neurology.

[16]  The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations , 2003, Movement disorders : official journal of the Movement Disorder Society.

[17]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[18]  E. Tolosa,et al.  Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial , 2007, The Lancet Neurology.

[19]  Carlo Colosimo,et al.  Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations , 2010, Movement disorders : official journal of the Movement Disorder Society.

[20]  W. Poewe,et al.  Scales to assess psychosis in Parkinson's disease: Critique and recommendations , 2008, Movement disorders : official journal of the Movement Disorder Society.

[21]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .

[22]  Y. Agid,et al.  Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[23]  L. Seeberger,et al.  A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and Dyskinesia , 2000, Clinical neuropharmacology.

[24]  K. Lyons,et al.  Electronic motor function diary for patients with Parkinson's disease: a feasibility study. , 2007, Parkinsonism & related disorders.

[25]  Stanley Fahn,et al.  Does levodopa slow or hasten the rate of progression of Parkinson’s disease? , 2005, Journal of Neurology.

[26]  William W. McDonald,et al.  Depression rating scales in Parkinson's disease: Critique and recommendations , 2007, Movement disorders : official journal of the Movement Disorder Society.

[27]  W. Poewe,et al.  Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[28]  D. Nyholm,et al.  Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease , 2005, Neurology.

[29]  G. Friehs,et al.  Development and initial validation of a screening tool for Parkinson disease surgical candidates , 2004, Neurology.

[30]  M. Stacy,et al.  Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson’s disease , 2007, Journal of Neural Transmission.

[31]  E. Tolosa,et al.  The Patient Card Questionnaire to Identify Wearing-off in Parkinson Disease , 2007, Clinical neuropharmacology.

[32]  F. Stocchi The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations , 2006, Expert opinion on pharmacotherapy.

[33]  O. Lindvall,et al.  Use and interpretation of on/off diaries in Parkinson’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[34]  R. Hauser,et al.  Parkinson's disease home diary: Further validation and implications for clinical trials , 2004, Movement disorders : official journal of the Movement Disorder Society.

[35]  A. M. de Noordhout,et al.  Detection of motor and non-motor symptoms of end-of dose wearing-off in Parkinson's disease using a dedicated questionnaire: a Belgian multicenter survey. , 2006, Acta neurologica Belgica.

[36]  M. Ceccaldi,et al.  Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling , 2002, Neurology.

[37]  E. Tolosa,et al.  End-of-dose Wearing Off in Parkinson Disease: A 9-Question Survey Assessment , 2006, Clinical neuropharmacology.

[38]  A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. , 2005, Archives of neurology.

[39]  P. Tuite,et al.  Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005) , 2008, Annals of neurology.

[40]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[41]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.